DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/04dce1/renal_cell_carcimo) has announced the addition of the "Renal Cell Carcinoma Drug Discoveries - what the future holds" report to their offering.
This is a very exciting time in the treatment of renal cell carcinoma (RCC)...
With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.
While the RCC market has traditionally constituted a relatively small segment of the oncology market, it has more recently attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma. Older immunotherapy regimens have now been replaced as the standard of care by the newer targeted therapies launched in recent years, namely Pfizers Sutent (sunitinib), Bayer/Onyx Nexavar (sorafenib), Roches Avastin (bevacizumab) and Pfizers Torisel (temsirolimus). Since the launch of these agents in 2005/2006, the RCC market has become a rapidly-growing segment, with almost US$2.2 billion spent on branded drugs in 2008.
Significant opportunities still exist for products to expand within this marketplace. A large percentage of patients are not currently treated with drug therapies and are not cured by surgery alone; patients with localised and locally-advanced disease represent a significant patient population that may be suitable for adjuvant therapy with targeted therapies. Established agents such as Sutent, Nexavar and Avastin are being investigated in the adjuvant setting, along with new therapies including Wilex Rencarex (girentuximab), currently in Phase III trials. In addition, many patients do not respond to current therapies, and more effective product introductions and greater use of combination therapies will address this clinical need for patients with metastatic RCC.
This report forecasts that sales of RCC treatments will increase substantially to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%
The number of patients by value in the US, Europe (top five countries) and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). We estimate that approximately 18% of the RCC patient population currently receives drug therapy. By 2015, we expect a higher percentage of patients to receive treatment, reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.
Key Topics Covered:
- Renal Cell Carcinoma
- Executive Summary
- The Facts
- Patient Statistics
- Patient Model
- Drug Growth Drivers
- Drug Growth Risks/Dampeners
- The Market
- Global Cancer Market
- The Rcc Market
- Global Sales Split
- Current Treatments
- Analysis Of Leading Brands
- Global Sales Forecasts Of Current Treatments 2005a2012e
- New Drugs In R&D
- Analysis Of Phase Iii Drugs
- Global Sales Forecasts Of Phase Iii Rcc Drugs 2006e2012e
- Analysis Of Phase Ii Drugs
- Global Sales Forecasts Of Phase Ii Rcc Drugs 2006a 2012e
- Competitor Ratio Analysis - Products
- Discontinuation Of Drugs
For more information visit http://www.researchandmarkets.com/research/04dce1/renal_cell_carcimo
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
INDUSTRY KEYWORDS: Health Oncology Pharmaceutical